Investors / Sweden / Eir Ventures
Eir Ventures
Venture capital · Stockholm, Sweden · Europe
Eir Ventures is a life science venture capital firm with offices in Stockholm, Sweden and Copenhagen, Denmark. It invests in and actively owns portfolio companies, taking board seats and supporting company creation.
Invests inHealthcare & Biotech
In its own wordslife sciencehealthcarebiotechnordicspharma
Your fit with Eir Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsEir Ventures lists 16 checked portfolio companies on its own site and is named in 3 funding rounds, 1 of them as lead. Its most frequent entry is Seed, 33% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 67% of its companies are based in Sweden. It invests most often alongside ARCH Venture Partners, GU Ventures and Altamont Pharmaceutical Holdings.
Counts come from funding rounds that name Eir Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Eir Ventures' whole history. Rounds on record name 3 companies; its own site lists 16. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundEir Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 33% |
| Series A | 0% |
| Series B | 33% |
| Growth | 33% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 0 | 0 |
| '26 | 3 | 1 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 42th | 16 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 64th | 33% of entries at pre-seed or seed |
| Evidence | 68th | 6% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 58th | 3 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| ARCH Venture Partners | 2 |
| GU Ventures | 2 |
| Altamont Pharmaceutical Holdings | 1 |
| Angelini Ventures | 1 |
| Avoro Capital Advisors | 1 |
| Bay City Capital | 1 |
| BioGeneration Ventures | 1 |
| BiomedVC | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers1594%
- No longer answers00%
- Points to another company16%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherAll co-investors or Compare portfolios with ARCH Venture Partners
Compare Eir Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Eir Ventures| Date | Company | Stage |
|---|---|---|
| 30 Apr 2026 | Series B | |
| 24 Apr 2026 | Seed | |
| 2 Apr 2026 | Series C+ Led |
Round details for Eir Ventures
Amounts, full round histories and every co-investor in Eir Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
16 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| ArgusEye provides real-time bioprocess monitoring solutions for the biopharmaceutical industry | Healthcare & Biotech | Portfolio page | ||
| ArgusEye develops and provides biosensor technology for real-time monitoring of bioprocesses in the biopharmaceutical industry | Healthcare & Biotech | Apr 2026Seed | Funding round | |
| Attgeno is involved in the development of targeted delivery of nitric oxide for saving patient lives | Healthcare & Biotech | Portfolio page | ||
| Cinclus Pharma develops small molecules for the treatment of gastric acid related diseases. | Healthcare & Biotech | Portfolio page | ||
Healthcare & Biotech | Portfolio page | |||
| GutCRINE pioneers pharmabiotics derived from gut microbiome hormone synthesis for prevention and treatment of cardio-metabolic disorders | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Hoba Therapeutics is an early-stage biotech developing innovative treatments for chronic pain disorders and sensorineural hearing loss | Healthcare & Biotech | Portfolio page | ||
| IO Biotech develops therapeutic cancer vaccines | Healthcare & Biotech | Portfolio page | ||
| Long Tail Health Solutions helps health systems with utilization management to improve their financial performance | Healthcare & Biotech | Apr 2026Series C+ | Funding round | |
| Moleculent is pioneering functional profiling, bringing cell-cell communication within reach of direct study and opening new possibilities for understanding disease. | Healthcare & Biotech | Apr 2026Series B | Page + round | |
| Pretzel Therapeutics is advancing a new class of medicines that target cellular energetics at its source. | Healthcare & Biotech | Portfolio page | ||
| Purpose Pharma is a European based pharmaceutical company focusing on the development and commercialization of innovative rare disease and specialty care products in areas of high unmet medical need. | Healthcare & Biotech | Portfolio page | ||
| Scenic Biotech is a neurometabolic company developing disease-modifying therapies that restore lysosomal function, a core driver of neurodegeneration. | Healthcare & Biotech | Portfolio page | ||
| Sortina Pharma develops differentiated small molecule therapeutics targeting sortilin to address life-threatening diseases. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page |
About this data
site last read 5 Nov 2026- Site
- eirventures.eu
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 2 Apr 2026
- Companies checked
- 16
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Eir Ventures' profile as data
Pull Eir Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/eirventures.eu
# also
GET /v1/firms/eirventures.eu/portfolio
GET /v1/firms/eirventures.eu/coinvestors
GET /v1/firms/eirventures.eu/news